• support@madhedgefundtrader.com
  • Biotech Model Portfolio
  • Daily Hot Tips
  • Hot Tips Archive
  • Member Login
  • Logout
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • My Account
    • Global Trading Dispatch
    • Mad Hedge Technology Letter
    • Biotech Newsletter
    • Newsletter
    • Mad Options Trader
    • Mad Hedge AI
    • Jacquie’s Post
    • Free Newsletter / Hot Tips
    • My Profile
      • Update Password
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
april@madhedgefundtrader.com

The Art Of War, Immunology Edition

Biotech Letter

Last month, as I pored over pharma earnings with a strong espresso and a stronger sense of deja vu, I was reminded why I swapped the lab coat for a Bloomberg terminal four decades ago.

Markets may not speak Latin, but they sure know how to butcher nuance. And AbbVie (ABBV), dear readers, is a textbook case of Wall Street wearing blinders while science quietly rewrites the rules.

Let me explain.

Back in my undergrad days at UCLA, I could wax poetic about enzyme kinetics and allosteric regulation. Today, I wax wealthier spotting when the Street completely misses the forest for the molecules.

AbbVie is no longer just “that Humira company” trying to outrun a patent cliff. It’s a leaner, meaner biotech beast building the next-generation immunology empire, but you’d never guess it from the recent selloff.

Yes, the bears have their spreadsheets out. Operating margins fell from a princely 32% in 2022 to a slightly flabby 22% in Q1 2025.

Free cash flow took a hit, down to $1.6 billion, and yet the dividend got hiked to $1.64 per share — an eyebrow-raising 180% payout ratio.

Toss in looming drug tariffs potentially costing $200-400 million annually, and you’ve got every value investor clutching their pearls.

But here’s the thing: the market is dissecting yesterday’s AbbVie, not today’s.

This is where Skyrizi and Rinvoq come in. These aren’t just Humira 2.0. They’re a masterclass in drug design.

Skyrizi’s every-eight-week dosing isn’t a marketing trick; it’s pharmacokinetic superiority with a side of patient loyalty.

In inflammatory bowel disease, these drugs now dominate over half of new prescriptions, not because they’re cheap, but because they work. Better. Faster. Smarter.

While the bears tally cash flows, AbbVie is tallying prescriptions. Skyrizi and Rinvoq racked up $5.2 billion in Q1 2025 alone, growing 65% year-over-year.

Management expects them to haul in $31 billion by 2027, showing off a tidy upgrade from Humira’s peak of $20 billion.

And AbbVie’s not stopping there.

Their migraine trio, Qulipta, Ubrelvy, and good old Botox, offers a full-spectrum approach from prevention to acute care. In Parkinson’s, Vyalev and Tavapadon bookend the treatment journey.

Now, about that red-hot weight loss space.

While Novo Nordisk (NVO) and Eli Lilly (LLY) joust over GLP-1s, AbbVie is quietly trialing an amylin analog that triggers 8% weight loss in six weeks, with fewer side effects and better muscle retention.

Even better, they can tap into their aesthetics division to reach cash-pay consumers the others can’t touch.

Yes, Q1’s cash flow dip looks ugly on paper. But it’s driven by working capital swings and litigation noise, not systemic rot.

The interest coverage ratio remains a healthy 9x, and the company has plenty of borrowing runway. The dividend bump, though aggressive, telegraphs confidence, not desperation.

Trading at 14x forward earnings with a 3.4% yield, AbbVie is a high-grade pharma stock masquerading as a value trap.

For comparison: Johnson & Johnson (JNJ) trades at 15x, and Lilly, riding its GLP-1 halo, fetches a nosebleed 37x. But AbbVie’s immunology crown jewels could rival or surpass both in growth.

Every time I’ve made a killing in pharma, it started with this same story arc: world-class science misunderstood by bean counters obsessing over quarterly quirks.

AbbVie didn’t just brace for Humira’s decline. They spent years building a pipeline designed to win on efficacy, not just exclusivity.

In other words, AbbVie is doing what great pharma does best: turning scientific precision into long-term profit. The market, bless its heart, is still squinting at last quarter’s cash flow like it’s reading tea leaves.

After decades of watching markets panic over the wrong metrics, I’ve learned to love it when brilliant science meets temporary pessimism. It’s like finding a Bordeaux first growth mislabeled as table wine. The fundamentals haven’t changed, just the price tag.

And frankly, after spending my college years memorizing biochemical pathways that I was certain would change the world, there’s something deeply satisfying about watching AbbVie actually do it — one precisely engineered molecule at a time.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-17 12:00:262025-06-17 14:03:43The Art Of War, Immunology Edition
april@madhedgefundtrader.com

June 17, 2025

Diary, Newsletter, Summary

Global Market Comments
June 17, 2025
Fiat Lux

 

Featured Trade:

(MARKET OUTLOOK FOR THE WEEK AHEAD, or THE IRAN WAR AND YOUR PORTFOLIO)
($SPX), ($WTIC), (TSLA), (QQQ), (TLT), (BA), (GLD)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-17 09:04:242025-06-17 14:05:41June 17, 2025
april@madhedgefundtrader.com

The Market Outlook for the Week Ahead, or The Iran War and Your Portfolio

Diary, Homepage Posts, Newsletter

If you are worried about the Israel-Iraq war causing a third oil shock and sending your portfolio to the junk yard, you can rest easy.

Only a few Israeli attacks targeted Iranian oil facilities. It helps that there is a global oil glut and widespread tax-subsidized overproduction. The Strait of Hormuz remains open, which I used to regularly fly over to watch the last tanker war back in the 1980s.

Last year, Iran produced 3.3 million barrels a day, nearly all of which went to China. Are we really sweating over China’s oil supply? But the American price of gasoline will rise, nonetheless. The US oil industry never wastes a war. At my local Chevron station, the price has already risen to $5.09 a gallon, up a buck on the week. It seems that gas station owners read the newspapers, too.

For now, it’s buy oil, sell equities. I had already written trade alerts to buy ExxonMobile (XOM) and Occidental Petroleum (OXY), but the Israelis beat me to the punch by a day. Up 40% on the year, I have no need to chase dubious and late trades.

If anyone doubted that insider trading was going on these days, look no further than the oil futures market, which began a dramatic rise on Monday and accelerated every day as rumors of an impending attack spread. Whether these are Israeli speculators or the home-grown variety is anyone’s guess.

Texas tea is now an impressive $17, or 30% off the May bottom. And it was climbing a wall of short positions in oil all the way, making the ascent even easier. There has been no actual disruption of supplies….yet. It is pure speculation that has taken oil prices northward.

If this does broaden out to a wider regional war, there will be consequences. Oil prices will soar to $100 or better. It will deepen the recession in the US, cause inflation to catch on fire, and send the S&P 500 back to 4,800 or lower. During the last oil shock in 1979, the US entered a three-year recession, inflation rose to 14%, and stocks fell 30%.

China will be the worst affected, which imports almost all of its oil. The US has, in fact, been weaning itself off Middle Eastern oil for decades and actually became energy independent on paper in 2015. However, specific Saudi oil types paired with matched US refiners will be hit, so there will be some disruption. A big recurring factor will be shipping insurance, which in the past has risen by 400% on these occasions.

Saudi Arabia now has a 746-mile East-West pipeline built in 1982 just for this contingency. It can carry 5 million barrels a day and 4 million barrels a day of excess production capacity to fill it. We didn’t have this during the last oil shock in 1979.

And in any case, the US is far less reliant on crude than it used to be. Barrels of oil per unit of GDP have been falling for 25 years. A new Lincoln Continental gets 25 miles per gallon instead of just eight.

A new Middle Eastern war DID renew the bid for gold and prompted me to double up my long position once again. I was looking at the gold and oil markets Friday morning and thought, “Gee, do I really want to buy oil up here”? The barbarous relic won out.

Emerging market central banks have been buying a massive 1,000 metric tonnes a year of the yellow metal as a US dollar alternative, and they are bound to continue. And gold loves uncertainty, which we have gobs of these days. It is the new “feel-good” investment.

The timing of the Israeli attack was interesting from another point of view. Ridiculously overbought stocks were just starting to roll over and were searching for a reason to fall. It’s now buy oil and sell equities. Is it possible that Tel Aviv has a technical analyst on staff?

If they don’t, they should.

With uncertainty reigning supreme and rising by the day, it’s looking like we may be stuck in a range for the rest of the year, from $5,500 for the ($SPX) on the low side to $6,500 on the high side. If we are lucky, we might get low single-digit returns for the year. It’s not the two back-to-back 20% years we saw in 2023-2024. But bull markets don’t live forever. The tough row to hoe is that’s all we might get for the next four years.

With the Volatility Index now well under $20, the easy money has been made this year. I increasingly feel like we are having to take increasing amounts of risk to achieve ever smaller returns. So I am going to shrink my book down to a minimum with the June 20 option expiration on Friday this week. After that, I’ll be waiting for the slow pitches to come to me.

By the way, the best way to strike out Babe Ruth was with a slow pitch (a great baseball player for you foreigners).

It was a good week for the Mad Hedge Fund Trader. My June performance raced up to +11.20%, taking us to new all-time highs on all metrics. That takes us to a year-to-date profit of +40.89%. My trailing one-year return exploded to a record +98.01%. That takes my average annualized return to +51.69%, the first time I‘ve hit the $51 handle ever, and my performance since inception to +792.18%.

It has been another tumultuous week. I took profits in long positions in (TSLA) and “RISK OFF” positions in (QQQ), (TLT), and (GLD). I added a new long in (BA) and rolled forward my “RISK OFF” position in (GLD) up and out. Some 17 of my last 18 positions have been profitable.

Some 63 of my 70 round trips in 2023, or 90%, were profitable. Some 74 of 94 trades were profitable in 2024, and several of those losses were really break-even. That is a success rate of +78.72%.

Try beating that anywhere.

Israel Attack on Iran Knocks Stocks, but not much. At the worst, the Dow Average was down 700 points. The big surprise was that bonds sold off as well in the wake of a successful 30-year auction yesterday. The weakness will continue as long as Israel continues to attack.

The First Half of 2025 is a Write-Off, with zero return on stocks. Of the 500 stocks in the S&P, 279 are up and 231 are up more than the Index. That is, unless you are a European or Japanese investor, where US stocks are still down 20% because of the collapse of the US dollar (FXY), (FXE), (FXB). Whole sectors of the US economy have been demolished, along with their stocks, including retailers, big pharma, energy, oil service, health care, utilities, railroads, overnight delivery, and consumer discretionary.

Oil prices Get a Rare Boost from the Israel Attack, up 8%. The U.S. said on Wednesday that personnel were being moved out of the Middle East because “it could be a dangerous place”, as the Iran nuclear talks stalled. Clearly, the US had advance notice of the attack. Non-essential personnel were sent home from the Baghdad embassy. Inflation is expected to accelerate in the coming months, prompted by America’s trade war.

Government Spending Hit a New All-Time High in May. Increased spending on Medicare and Homeland Security was a big factor. After running a short-lived surplus in April thanks to tax season receipts, the deficit totaled just more than $316 billion for the month, taking the year-to-date total to $1.36 trillion. The defect is now 14% higher than a year ago.

Tariff Revenues Hit New All-Time High, at $23 billion in May, up 60% YOY. US customs duties climbed to a record in May, helping shrink the budget deficit for the month, while doubts remain about the persistence of the inflows as the administration negotiates with trading partners and faces a judicial challenge over its levies.

The Core Inflation Rate Comes in Light, up 0.1% MOM in May to 2.4%. Food prices were up 0.3%. The report from the Labor Department on Wednesday also showed underlying price pressures muted last month. Economists say inflation has been slow to respond to sweeping tariffs, as most retailers are still selling merchandise accumulated before the import duties took effect. Next month’s report for June should show the first impact of tariffs.

Assets held in crypto funds hit a record high in May, as easing trade tensions lifted risk appetite and some investors used the digital currencies to hedge against market volatility and diversify from their U.S. holdings. Morningstar data on 294 crypto funds shows they attracted $7.05 billion in net inflows last month, the highest since December, bringing total assets under management to a record $167 billion.

Boeing (BA) heads into the Paris Air Show after booking 300 new orders and rolling out 38 new 737 MAX jets, a production rate it has been working to reach for more than a year. The company also delivered 45 aircraft last month. It was the sixth-highest monthly order tally in Boeing’s history, according to company data.

The orders included the largest widebody jet deal in Boeing’s history. A massive Qatar Airways order accounted for 130 Boeing 787s and 30 Boeing 777Xs, plus options for another 50 of the long-haul aircraft. It looks like the turnaround is here.

Market Volatility is Collapsing, with the Volatility Index ($VIX) down to the $16 handle, predicting a flat summer for equities. Implied volatilities for options are also in free fall, with Tesla options down from 85% to 55% over the weekend. That would give stocks a zero return for the year through September for 2025. Good thing we coined it when volatility was at extremes.

Administration Proposes 20% Withholding Tax on Foreign Corporations doing business in the US. The House Bill, known as Section 899, would allow the U.S. to add a new tax of up to 20% on foreigners with U.S. investments, including multinational companies operating in the U.S..  Some analysts call the provision a “revenge tax” due to its wording. It would apply to foreign entities if their home country imposes “unfair foreign taxes” against U.S. companies, which is virtually everyone. I can’t think of a better way to scare foreign investment away from the US.

Tesla is the Worst-Performing Large-Cap Stock this Year, suffering a $380 billion capital loss. Elon Musk’s personal hit was $75 billion. You can thank declining electric vehicle demand, Musk’s political controversies over his ties to far-right groups, and a very public feud with the president.  I made a killing covering my Tesla shorts. I then used triple-digit option implied volatility to go cautiously long through $100 extremely deep in-the-money spreads. Tesla isn’t going to zero.

My Ten-Year View – A Reassessment

We have to substantially downsize our expectations of equity returns in view of the election outcome. My new American Golden Age, or the next Roaring Twenties, is now looking at multiple gale-force headwinds. The economy will completely stop decarbonizing. Technology innovation will slow. Trade wars will exact a high price. Inflation will return. The Dow Average will rise by 600% to 240,000 or more in the coming decade. The new America will be far more efficient and profitable than the old. My Dow 240,000 target has been pushed back to 2035.

On Monday, June 16, at 8:30 AM, the New York Empire State Manufacturing Index is printed.

On Tuesday, June 17, at 7:30 AM, the Retail Sales are announced.

On Wednesday, June 18, at 1:00 PM, we get the Fed Interest Rate Decision. We also get the Housing Starts and Building Permits, and Weekly Jobless Claims.

On Thursday, June 19, is a National Holiday, Juneteenth, and all financial markets are closed. This is the first time Juneteenth is a national holiday.

On Friday, June 20, at 7:30 AM, we get the Philadelphia Fed Manufacturing Index. At 1:00 PM, the Baker Hughes Rig Count is published.

As for me
,
during the late 1980s, the demand for Japanese bonds with attached equity warrants was absolutely exploding.

Japan was Number One, the engine of technological innovation. Everyone in the world owned a Sony Walkman. They were trouncing the United States with 45% of its car market.

The most conservative estimate for the Nikkei Average for the end of 1990 was 50,000, or up 27%. The high end was at 100,000. Why not? After all, the Nikkei had just risen tenfold in ten years, and the Japanese yen had tripled in value.

In 1989, my last full year at Morgan Stanley, the Japanese warrant trading desk accounted for 80% of the firm’s total equity division profits.

The deals were coming hot and heavy. Since Morgan Stanley had the largest Japanese warrant trading operation in London, a creation of my own, we were invited to join so many deals that the firm ran out of staff to attend the signings.

Since I was the head of trading, I thought it odd that the head of investment banking wanted to speak to me. It turned out that Morgan Stanley was co-managing two monster $3 billion bond deals on the same day. Could I handle the second one? Our commission for the underwritings was $10 million for each deal!

I thought, why not? Better to see how the other half lived. So, I said “yes.”

The attorneys showed up minutes later. I was given a power of attorney to sign on behalf of the entire firm and commit our capital to the underwriting $3 billion, five-year bond issue for the Industrial Bank of Japan. The deal was especially attractive as the bonds carried attached put options on the Nikkei, which institutional investors could buy to hedge their Japanese stock portfolios.

Since the Industrial Bank of Japan thought the stock market would never see a substantial fall, they happily sold short the put options. Only the Industrial Bank of Japan could have pulled this off, as it was one of the largest and highest-rated banks in Japan. I knew the CEO well.

It turned out that there was a lot more to a deal signing than I thought, as it was done in the traditional British style. We met at the lead manager’s office in the City of London in an elegant wood-paneled private dining room filled with classic 18th-century furniture.

First, there was a strong gin and tonic which you could have lit with a match. A five-course meal accompanied by a 1977 deep Pouilly-Fusé white and a 1952 Bordeaux red with authority. I had my choice of elegant desserts. Sherry and a 50-year-old port followed, along with Cuban cigars, which was a problem since I had just quit smoking (my wife recently bore twins).

The British were used to these practices. Any American banker would have been left staggering, as drinking during business hours back then was illegal in New York.

Then out came the paperwork. I signed with my usual flourish, and the rest of the managers followed. The Industrial Bank of Japan provided the Dom Perignon as they were about to receive $3 billion in cash the following week.

Then an unpleasant thought arose in the back of my mind. Morgan Stanley assumed the complete liability for their share of the deal. But did I just incur a massive personal liability as well?

Then I thought, naw, why pee on someone’s parade? Morgan Stanley’s been doing this for 50 years. Certainly, they knew what they were doing.

Besides, the Japanese stock market is going up forever, right? No harm, no foul. In any case, I left Morgan Stanley to start my own hedge fund a few months later.

Some seven months later, one of the greatest stock market crashes of all time began. The Nikkei fell 50% in six months and 85% in 20 years. Some 32 years later, the Nikkei still hasn’t recovered its old high.

For a few years, that little voice in the back of my mind recurred. The bonds issued by the Industrial Bank of Japan fell by half in months due to rocketing credit concerns. The IBJ’s naked short position in the Nikkei puts completely blew up, costing the bank $10 billion. The Bank almost went bankrupt. It was one of the worst-timed deals in the history of finance. The investors were burned big time.

Did I ever hear about the deal I signed again? Did process servers show up at my front door in London with a giant lawsuit? Did Scotland Yard chase me down with an arrest warrant?

Nope, nothing, nada, bupkis. I never heard a peep from anyone. It turns out you CAN lose $12 billion worth of other people’s money and face absolutely no consequences whatsoever.

Welcome to Wall Street.

Still, when the five-year maturity of the bonds passed, I breathed a sigh of relief.

My hedge fund got involved in buying Japanese equity warrants, selling short the underlying stock, creating massive short positions with a risk-free 40% guaranteed return. My investors loved the 1,000% profit I eventually brought in doing this.

Unlike most managers, I insisted on physical delivery of the warrant certificates, as the creditworthiness of anyone still left in the business was highly suspect. Other managers who took physical delivery used their warrants to wallpaper their bathrooms (really).

They all expired worthless. I made fortunes shorting the stock, and still have the warrants today by the thousands (see photo below).

In September 2000, the Industrial Bank of Japan, with its shares down 90%, merged with the Dai-Ichi Kangyō Bank and Fuji Bank to form the Mizuho Financial Group. It was a last-ditch effort to save the Japanese financial system after ten years of recession.

Morgan Stanley shut down their worldwide Japanese equity warrant trading desk, losing about $20 million and laying off 200. Some staff were outright abandoned as far away as Hong Kong. Morgan Stanley was not a good firm for running large losses, as I expected.

I learned a valuable trading lesson. The greater the certainty that people have that an investment will succeed, the more likely its failure. Think of it as Chaos Theory with a turbocharger.

But we sure had a good time while the Japanese equity warrant boom lasted.

 

 

 

Good Luck and Good Trading,

John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

 

 

 

 

 

 

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2016/12/john-tokyo.jpg 425 318 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-17 09:02:122025-06-17 14:05:07The Market Outlook for the Week Ahead, or The Iran War and Your Portfolio
DougD

June 17, 2025 – Quote of the day

Diary, Newsletter, Quote of the Day

“Almost all asset markets are bubbles and mispriced,” said Bill Gross of bond giant PIMCO.

Kids - Bubbles

https://www.madhedgefundtrader.com/wp-content/uploads/2014/04/Kids-Bubbles.jpg 283 426 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2025-06-17 09:00:532025-06-17 14:02:54June 17, 2025 – Quote of the day
Douglas Davenport

The Health Assurance Revolution: How AI’s Next Breakthrough Could Reshape Healthcare, According to General Catalyst CEO Hemant Taneja

Mad Hedge AI

The healthcare industry, a sector historically characterized by its reactive “sick care” model, stands at the precipice of a profound transformation. Driving this impending revolution is Artificial Intelligence, a powerful force poised to redefine everything from diagnostics and drug discovery to patient engagement and the very economics of care. At the heart of this visionary shift is Hemant Taneja, CEO of General Catalyst, a venture capital firm that isn’t merely investing in the future of healthcare – it’s actively seeking to shape it, believing that AI’s next monumental breakthrough will fundamentally shift healthcare towards a proactive, accessible, and affordable “Health Assurance” paradigm.

Taneja’s perspective, famously articulated in his 2020 book “UnHealthcare: A Manifesto for Health Assurance” co-authored with Dr. Stephen Klasko, former CEO of Jefferson Health, argues for nothing less than a systemic overhaul. He envisions a world where health is not just restored after illness, but continuously maintained and assured through proactive, personalized care. This ambitious shift, Taneja contends, is overwhelmingly achievable through the strategic and responsible deployment of AI across the entire healthcare continuum. General Catalyst’s deep conviction in this future is evident in its aggressive investment strategy and groundbreaking partnerships, from co-creating companies like Hippocratic AI to forging ambitious collaborations with technology giants such as Amazon Web Services (AWS) to accelerate AI innovation within major health systems.

The current healthcare system grapples with a litany of well-documented challenges: spiraling costs that threaten national economies, rampant provider burnout leading to staffing crises, stark inequities in access to quality care, and a pervasive, entrenched focus on treating symptoms rather than preventing disease. Hemant Taneja believes AI offers a powerful, multi-faceted antidote to many of these systemic ailments. General Catalyst is placing significant bets on breakthroughs across several pivotal areas, each designed to address a critical pain point within the existing framework.

Reinventing Care Delivery: From Reactive to Proactive Wellness

Perhaps the most profound impact of AI in healthcare, as championed by Taneja, lies in its capacity to facilitate a definitive shift from reactive “sick care” to proactive “health assurance.” This paradigm involves leveraging AI not just to address existing illnesses, but to predict and prevent health issues before they ever escalate, fundamentally changing how individuals interact with the healthcare system.

Predictive Analytics and Early Detection: Imagine a future where serious illnesses are often caught not just early, but before they even manifest. AI algorithms, capable of analyzing vast and disparate datasets – including genomic profiles, comprehensive electronic health records, continuous data streams from wearable devices, and even nuanced insights into social determinants of health – are making this a reality. These sophisticated models can identify individuals at remarkably high risk for specific conditions, from cardiovascular disease to certain cancers. For instance, AI is already demonstrating the unprecedented capability to detect the subtle markers of conditions like Alzheimer’s, chronic obstructive pulmonary disease, and early-stage kidney disease years before overt symptoms appear. This unparalleled early identification empowers healthcare providers to implement timely interventions and highly personalized preventative strategies, dramatically improving long-term outcomes and potentially averting the need for costly, intensive treatments further down the line.

True Personalized Medicine and Treatment Optimization: The long-held “one-size-fits-all” approach to medical treatment is rapidly becoming obsolete. AI is the key to unlocking genuinely personalized medicine. By meticulously processing an individual’s unique biological, genetic, and lifestyle data, AI can recommend therapies precisely tailored to their specific needs. This includes accurately predicting a patient’s likely response to different medications, meticulously optimizing dosages to maximize efficacy and minimize side effects, and even designing bespoke, multi-modal treatment plans for complex and chronic diseases. This unprecedented level of precision promises to significantly enhance treatment efficacy, dramatically reduce adverse drug reactions, and ultimately, elevate patient quality of life to an entirely new standard.

Remote Patient Monitoring and the Expansion of Virtual Care: The global COVID-19 pandemic acted as an unforeseen accelerator for the adoption of telehealth and remote patient monitoring (RPM). AI is now poised to revolutionize these modalities even further, making them more robust and pervasive. AI-powered RPM solutions can continuously track an array of vital signs, activity levels, sleep patterns, and other crucial health metrics from the comfort and convenience of a patient’s home. These intelligent systems are designed to alert healthcare providers to even subtle changes that might indicate a deteriorating condition, often before the patient themselves notices. This continuous, proactive monitoring is particularly vital for the effective management of chronic diseases and for providing high-quality support to patients in remote or underserved areas, effectively extending the reach of expert healthcare far beyond the traditional confines of clinics and hospitals.

Augmenting the Workforce and Unleashing Unprecedented Efficiency

Healthcare professionals globally are grappling with unprecedented levels of burnout, exacerbated by crushing administrative burdens, relentless paperwork, and persistent staffing shortages. Hemant Taneja sees AI as not just a tool, but a powerful “co-pilot,” meticulously designed to alleviate these systemic pressures and empower clinicians to operate at the absolute peak of their licenses and expertise.

Streamlining Administrative Workflows: A staggering portion of a healthcare professional’s day is consumed by administrative duties – meticulously charting patient encounters, navigating complex billing procedures, managing intricate scheduling, and tirelessly retrieving disparate pieces of information. AI-powered solutions, particularly advanced large language models (LLMs) and intelligent automation platforms, are demonstrating remarkable capabilities in automating many of these historically mundane and time-consuming tasks. For instance, AI tools can now seamlessly listen to clinical consultations and automatically generate comprehensive, accurate notes in real-time, freeing up doctors to maintain unbroken eye contact and focus entirely on patient interaction and empathy. This not only dramatically boosts efficiency but also significantly reduces the likelihood of human error, leading to more accurate medical records and far smoother operational flows.

Enhanced Diagnostic Accuracy and Medical Imaging: AI is already making monumental inroads in the field of medical imaging, where sophisticated algorithms can analyze X-rays, MRIs, CT scans, and other diagnostic images with astonishing speed and precision, frequently surpassing human capabilities in detecting subtle anomalies that might otherwise be missed. AI can assist radiologists in identifying minute fractures, spotting tiny or obscured lesions in brain scans, detecting early signs of cancer, and even intelligently triaging critical cases that require immediate attention. This powerful augmentation of diagnostic capabilities leads directly to earlier, more accurate diagnoses, enabling prompt and life-saving treatment.

“Super Staffing” with Intelligent AI Agents: General Catalyst, through its innovative co-creation of Hippocratic AI, is actively exploring and demonstrating the transformative concept of “super staffing” the clinical workforce with highly specialized AI agents. These AI agents are meticulously trained and designed to handle a broad spectrum of low-risk, non-diagnostic patient-facing services. This includes efficiently answering routine patient queries, providing clear and concise post-discharge instructions, offering comprehensive basic health education, and even managing appointment reminders. By expertly offloading these repetitive yet essential tasks, human clinicians gain invaluable time to concentrate on complex medical decision-making, providing deeply empathetic care, and performing critical interventions, thereby significantly increasing overall provider capacity and ensuring greater scalability of healthcare services.

Accelerating Medical Innovation: From Lab to Life

The process of drug development is notoriously protracted, extraordinarily expensive, and fraught with an alarmingly high failure rate. AI offers a revolutionary paradigm shift in this domain, promising to dramatically accelerate the pace of medical innovation and bring life-saving therapies to patients much faster.

Expedited Drug Discovery and Development: AI algorithms possess the unprecedented ability to analyze colossal chemical and biological datasets, identify potential drug candidates with remarkable accuracy, predict their likely efficacy and potential toxicity, and even design novel molecular structures from scratch. This capability significantly shortens both the time and the exorbitant cost associated with preclinical research and development, allowing pharmaceutical companies to bring promising new treatments to market at an accelerated pace. The rapid identification of drugs like Olumiant as a potential treatment for COVID-19, significantly facilitated by AI-driven insights, stands as a powerful and compelling testament to this transformative capability.

Optimizing Clinical Trials for Efficiency: AI can fundamentally enhance the design, patient recruitment, and ongoing monitoring of clinical trials. By meticulously analyzing vast amounts of patient data, AI can intelligently identify the most suitable candidates for trials, predict patient adherence rates, and monitor treatment outcomes far more effectively and continuously. This leads to significantly more efficient and successful trials, ultimately ensuring that groundbreaking, life-saving therapies reach patients who need them most in a fraction of the traditional timeframe.

Revolutionizing Medical Research and Unlocking New Insights: AI possesses an unparalleled ability to rapidly sift through mountains of medical literature, countless research papers, and complex patient data to identify previously undiscovered patterns, subtle correlations, and profound insights that would be virtually impossible for human researchers to discern manually. This extraordinary capability empowers scientists and medical researchers to develop groundbreaking new hypotheses, uncover novel disease mechanisms, and dramatically accelerate the overall pace of scientific discovery, leading to unforeseen advancements in medical understanding.

Navigating the Future: Challenges and the Path Forward

While the potential of AI in healthcare is nothing short of immense and transformative, its widespread adoption and integration are not without significant challenges. Hemant Taneja and General Catalyst are vocal proponents of a “Responsible Innovation” framework, emphasizing the critical need to proactively address crucial considerations such as:

Paramount Data Privacy and Ironclad Security: Healthcare data is, by its very nature, among the most sensitive and private information an individual possesses. The extensive use of AI in this sector necessitates the implementation of robust, cutting-edge safeguards to rigorously protect patient privacy and meticulously prevent data breaches. Ethical frameworks, stringent regulatory guidelines, and robust legal frameworks must evolve rapidly to keep pace with technological advancements, ensuring secure, transparent, and unequivocally responsible data handling practices.

Mitigating Algorithmic Bias and Ensuring Equity: AI models, by their very design, are only as unbiased as the data upon which they are trained. Historical healthcare data, unfortunately, often reflects existing societal biases and systemic inequities, which could potentially lead to disparities in care if not meticulously addressed and mitigated. The development of diverse and truly representative datasets, coupled with rigorous testing, continuous validation, and transparent auditing of algorithms, is absolutely crucial to ensure equitable and just outcomes across all patient populations, regardless of background.

Building Trust and Fostering Acceptance: Building profound trust among both clinicians and patients is an absolutely paramount prerequisite for the successful widespread adoption of AI. Healthcare professionals need a deep understanding of how AI tools function, confidence in their accuracy and reliability, and clear insights into their limitations. Patients, in turn, need transparent reassurance about the ethical use of their personal health data and a clear understanding of the precise role AI plays in their care journey. Transparency, empathetic communication, comprehensive education, and a consistently maintained human-in-the-loop approach are all essential components for fostering this foundational trust.

Seamless Integration into Existing Workflows: The healthcare system is, by its very nature, incredibly complex, deeply entrenched in established workflows, and often resistant to rapid change. Seamlessly integrating new, cutting-edge AI technologies into these intricate existing systems requires meticulous planning, robust interoperability solutions that allow disparate systems to communicate effectively, and significant, sustained investment in upgraded IT infrastructure and comprehensive clinician training programs.

Hemant Taneja’s vision for the future of healthcare is undeniably audacious yet deeply pragmatic and grounded in a clear understanding of technological potential. By focusing relentlessly on “Health Assurance” and strategically leveraging AI as a foundational, pervasive building block, General Catalyst is not merely seeking financial returns. Instead, it is actively working towards creating a more resilient, profoundly accessible, and genuinely equitable healthcare ecosystem for generations to come. The next truly monumental breakthrough in AI will not be a singular, isolated discovery, but rather the powerful, synergistic, and cumulative impact of these intelligent systems meticulously weaving themselves into the very fabric of healthcare, transforming it from a system that primarily reacts to illness into one that proactively assures well-being and vitality for all. As AI continues its rapid, relentless evolution, the inspiring prospect of a truly preventative, profoundly personalized, and universally affordable healthcare future, championed by visionary leaders like Hemant Taneja, draws ever closer to becoming a tangible, widespread reality.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2025-06-16 17:00:592025-06-16 17:05:37The Health Assurance Revolution: How AI’s Next Breakthrough Could Reshape Healthcare, According to General Catalyst CEO Hemant Taneja
april@madhedgefundtrader.com

June 16, 2025

Tech Letter

Mad Hedge Technology Letter
June 16, 2025
Fiat Lux

 

Featured Trade:

(QUALCOMM PIVOTS TO AI)
(QCOM)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-16 14:04:382025-06-16 14:31:00June 16, 2025
april@madhedgefundtrader.com

Qualcomm Pivots To AI

Tech Letter

Chips companies continue to overcome any type of challenge thrown at them.

They climb a wall of worry and keep chugging along.

Of course, it helps that they are the cornerstone of the U.S. stock market, with the AI demand causing investors to throw money at these stocks.

They also have policy support with for example, the U.S. CHIPS and Science Act that provides $39 billion in subsidies.

Sounds like a good deal, right?

This is why I have dove headfirst into chip trades like the one I executed on in Qualcomm (QCOM).

A buy-and-hold strategy would also suffice, because these stocks can get wild in the short-term.

Price action is not for the faint of heart.

Why invest in QCOM?

They are clear leaders in mobile technology while also mixing in high-growth sectors like AI, automotive, and IoT, robust financial performance, and an attractive valuation.

The smartphone market is showing signs of recovery after a cyclical downturn. Industry estimates project mid-single-digit growth in global handset sales through 2025, driven by 5G adoption and new device launches.

June often marks the ramp-up for summer product cycles, with manufacturers like Samsung and Xiaomi unveiling new models powered by Qualcomm’s chipsets.

Another short-term catalyst is Qualcomm’s recent $2.4 billion acquisition of Alphawave Semi, announced in June 2025.

Alphawave, a UK-based leader in high-speed connectivity for AI and data centers, enhances Qualcomm’s portfolio in the booming AI infrastructure market.

This acquisition aligns with the growing demand for power-efficient computing, as data centers scale to support AI workloads.

Qualcomm’s long-term investment case is rooted in its strategic diversification beyond smartphones, positioning it as a leader in multiple high-growth sectors. The company is transitioning from a mobile-centric chipmaker to a diversified technology provider, with significant exposure to AI, automotive, IoT, and PCs. This balanced portfolio reduces reliance on any single market, enhancing long-term stability and growth potential.

Qualcomm is at the forefront of on-device AI, a trend expected to redefine consumer electronics. Its Snapdragon platform, optimized for AI tasks like natural language processing and image recognition, powers “offline AI phones” that are gaining traction.

Data suggest Qualcomm could dominate this space, as its chips are integrated into mainstream Android devices from brands like Samsung, Xiaomi, and Google.

The Alphawave acquisition further strengthens Qualcomm’s position in AI data centers, a market projected to grow at over 20% through 2030.

Qualcomm’s automotive business is a major long-term growth driver. The company’s chips power connected car systems, infotainment, and autonomous driving features, with automotive revenue growing at over 30% in recent years.

Qualcomm’s IoT portfolio, spanning smart homes, industrial devices, and wearables, is another growth engine. The company’s chips are embedded in billions of devices, generating steady royalty income.

QCOM’s expansion into the AI infrastructure market shows they are betting big in this part of tech, and that won’t stop anytime soon.

They are also highly productive in the mobile technology segment, which is booming these days.

Dividend and shareholder buybacks underscore how QCOM’s management is focused on returning value to the shareholders.

It’s really the right company in the right sub-sector of tech.

I am bullish on QCOM after the stock is on discount from the low $200 price range.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-16 14:02:292025-06-16 14:30:41Qualcomm Pivots To AI
april@madhedgefundtrader.com

June 16, 2025

Jacque's Post

 

(THE ENERGY SECTOR HAS EMERGED FROM THE QUIET CORNER)

 

June 16, 2025

 

Hello everyone

 

WEEK AHEAD CALENDAR

Monday, June 16

8:30 a.m. Empire State Index (June)

Bond market: Auction 20-year bond

11:00 p.m. Japan Rate Decision

Previous: 0.5%

Forecast: 0.5%

Earnings: Lennar

 

Tuesday, June 17

8:30 a.m. Export Price Index (May)

8:30 a.m. Import Price Index (May)

8:30 a.m. Retail Sales (May)

Previous: 0.1%

Forecast: -0.5%

8:30 a.m. Capacity Utilization (May)

9:15 a.m. Industrial Production (May)

9:15 a.m. Manufacturing Production (May)

10:00 a.m. Business Inventories (April)

10:00 a.m. NAHB Housing Market Index (June)

Bond market: Auction 5-year TIPS

Earnings: Jabil

 

Wednesday, June 18

8:30 a.m. Building Permits preliminary (May)

8:30 a.m. Continuing Jobless Claims (06/07)

8:30 a.m. Housing Starts (May)

8:30 a.m. Initial Claims (06/14)

2:00 p.m. FOMC Decision

Previous: 4.5%

Forecast: 4.5%

2:00 p.m. Fed Funds Target Upper Bound

 

Thursday, June 19

7:00 a.m. UK Rate Decision

Previous: 4.25%

Forecast: 4.25%

Markets closed for Juneteenth National Independence Day

 

Friday, June 20

2:00 a.m. UK Retail Sales

Previous: 1.2%

Forecast: -0.5%

8:30 a.m. Philadelphia Fed Index (June)

10:00 a.m. Leading indicators (May)

Earnings: Darden Restaurants, CarMax, Kroger

 

A looming supply crisis could send energy stocks jumping strongly to the upside.

Around a month ago, I wrote about what was sitting in the “quiet corner”.  It was energy.

Since that time, energy names have been bouncing strongly, oil is breaking to the upside and as technical analyst, David Bird suggests, the macro setup suggests this may only be the beginning.

We are seeing a shuffling of the deck chairs, with smart money rotating into the sector that feeds tech and AI: energy.

Let’s not forget that the U.S. Strategic Petroleum Reserve (SPR) is basically America’s emergency oil reserve. The oil crisis of the 1970s saw the creation of this reserve to ensure the country had a back-up fuel in case of supply disruptions.

Over the past couple of years, the U.S. government has released more than 200 million barrels from this reserve to help bring down inflation and lower fuel prices, and consequently, this has left the reserve at its lowest level since the early 1980s.  There is no solid plan to refill it soon either.

The macro background behind the U. S’s oil reserves carries many risks.  We have the Middle East conflict, and the war in Ukraine, and oil production limits in countries like Venezuela and those in OPEC.  Supply is tight, demand is rising, and our safety buffer is dwindling.

Interestingly, Bird, among others, points out that it was the Biden administration that authorised the drawdown, and Trump’s “drill, baby, drill” is a direct response to this self-imposed energy vulnerability.

The AI boom will be an energy vampire.  The International Energy Agency (IEA) is drawing attention to the fact that electricity demand from AI and crypto mining could increase up to 10x by 2030. 

If oil can now stay above $65 – and confirm buyers have taken control – this move could mark a significant turning point in the overall macro trend.

For ways to get involved in this unfolding narrative, Bird and other analysts suggest the following –

For Australian investors:

For Growth + Dividends:

 

Woodside Energy (WDS)

Australia’s largest independent oil and gas producer, with a strong cash flow and a strong history of consistent dividend payments. 

For Stability and LNG Leverage:

 

Santos (STO)

The company has large-scale LNG operations across the Asia-Pacific region and shows consistent capital returns, as well as clear project pipelines.  There is also potential M&A activity that could see the stock re-rated.

For Pure Growth

 

Beach Energy (BPT)

This mid-cap company has exposure to Australian and New Zealand gas and is gaining attention during this market rotation. 

For a Leveraged Oil Play:

 

Betashares Crude Oil ETF (OOO)

This ETF tracks the price of crude oil futures – it is not a long-term hold and is best used for short to medium-term momentum plays.

For U.S. investors

 

United States Oil Fund ETF(USO)

This ETF tracks the price of light, sweet crude oil. Only to be used as a short-term play.

 

Occidental Petroleum (OXY)

This company is focused on exploration and production of oil and gas with operations in the U.S., Latin America and the Middle East.  Dividend yield = 2.14%

 

Exxon Mobile (XOM)

This company is involved in the exploration, production, refining and distribution of oil and gas. It produces 3% of the world’s oil and 2% of the world’s energy. (XOM) has been operating for more than 135 years and is the seventh largest company by revenue in the U.S. and the 13th largest in the world. It has an attractive dividend – 4.3% over the last 12 months – and is undervalued.

 

Cameco Corp. (CCJ) 

Cameco is the world’s largest publicly traded uranium company. Highest price targets from analysts = $106, and the lowest = $86, so more upside is possible this year.

 

Energy Select Sector SPDR Fund (XLE) ETF

This ETF includes companies that primarily develop and produce crude oil and natural gas and is an effective representation of the energy sector of the S&P500 index.  A good buy when a sector shift happens and we see oil strength.

On the 10/10/24 I suggested to all Jacquie’s Post subscribers to scale in or add weight to one or more of these utility and energy stocks.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Jacquie’s Post portfolio holds the following energy stocks:

 

 

 

 

 

 

 

 

 

 

Energy is no longer in the quiet corner.  The narrative is shifting.  Assess your position in relation to this regime change.

MARKET UPDATE

S&P500

The index could mark time here after its recent surge since April.  This could be a top for a month or so.  We may see a sideways/rangebound market or a sell off to 1st support level.   Interestingly, the index has bounced strongly since falling on Friday after Israel sent missiles into Iran.

Resistance = 6030/45 and 6140/55

Support = 5900/15 and 5795/10

GOLD

Gold is still ranging – likely a part of a larger topping story. We would need to see a very strong breakout above key resistance ($3465/75) to put this topping pattern on hold.

Support = $3325/30/$3205/15

BITCOIN

Bitcoin has stalled since reaching the new high of $112k.  There is scope now for more choppy/topping pattern behaviour, before a larger downside is seen. 

Resistance: 106.5/107.0k/110.1/110.6k and 112/113k area.

Support: 102.7/103.2k, 100.0/100.4k and 97.5/98.0k. 95.0k/90.0k also possible.

 

 

HISTORY CORNER

On June 16

 

 

QI CORNER

 

Syz Private Banking

 

 

Syz Private Banking

SOMETHING TO THINK ABOUT

 

 

Cheers

Jacquie

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-16 12:00:402025-06-16 12:15:25June 16, 2025
april@madhedgefundtrader.com

Tech Alert – (CRWD) June 16, 2025 – TAKE PROFITS – SELL

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-06-16 10:45:292025-06-16 10:45:29Tech Alert – (CRWD) June 16, 2025 – TAKE PROFITS – SELL
Douglas Davenport

THE DEATH OF MAD MEN

Mad Hedge AI

(META), (NFLX), (NKE), (SBUX), (GOOGL), (AMZN)

Last month, while visiting my daughter at UC Berkeley, I watched her roommate launch a digital blitzkrieg for her grandma’s cookie business using nothing but an iPhone, a $50 budget, and AI tools that would’ve made Don Draper weep into his Old Fashioned.

Within hours, AI had cranked out three slick video ads, sniffed out 2,847 sugar-craving locals within a 15-mile radius, and was delivering a 4.2x return on ad spend. Madison Avenue? That would’ve taken six weeks and a $50,000 tab (not counting the catered lunches).

That’s when the penny dropped: Meta Platforms (META) isn’t a social media company anymore. They’re building the world’s first fully automated advertising agency, and they’re doing it with ruthless efficiency. 

As for the traditional ad agencies? They’re now the candle makers after Edison got to work.

Here’s how this machine actually works. Meta’s AI is like a digital sommelier, except instead of wine pairings, it matches ads with eyeballs. And it never forgets a taste. It remembers every click, pause, scroll, and “meh” face from 3.43 billion users, refining its pitch like a stand-up comic working toward a Netflix (NFLX) special.

Compare that to traditional advertising, which resembles a shotgun blast: noisy, expensive, and mostly guesswork. Meta’s AI, on the other hand, is a laser-guided missile that adjusts in real-time for user mood, weather, and probably what you had for breakfast. 

But here’s the kicker: it’s not just targeting anymore. The AI is now crafting the ads itself.

Which brings me to Meta’s master plan. By 2026, they’re planning to fully automate ad creation and targeting — a natural evolution following their 2022 launch of Advantage+ campaigns, which already handle most media buying and creative optimization. 

Picture your local cupcake shop uploading a photo and a budget, and Meta’s AI spits out a full campaign, including videos, captions, and audience segments, faster than you can say “crème brûlée.”

Now scale that up. Every bakery, yoga studio, and Etsy knitter on Earth suddenly gets Madison Avenue-quality campaigns. 

Small businesses using Meta’s AI automation can expect to save 10–17% on core ad costs, with added gains in efficiency and return on ad spend. 

Translation? Advanced digital advertising is no longer just a Fortune 500 playground. The florist down the street just got superpowers.

This is where Wall Street completely misses the boat. Meta earns 97% of its $160 billion annual revenue from advertising, yet analysts are calling for a measly 7% EPS growth — the same crowd who probably thought the iPhone was a fad. Meanwhile, Meta just delivered 37% EPS growth in Q1 after a blockbuster 60% year in 2023.

Here’s what these spreadsheet warriors don’t grasp: Meta’s AI revolution creates twin profit engines. 

First, it democratizes slick advertising for millions of small businesses previously priced out of the game. 

Second, it forces big brands to bid more aggressively just to stay visible as competition explodes. When Nike (NKE) and Starbucks (SBUX) suddenly have to outbid every mom-and-pop shop for eyeball time, ad prices go through the roof.

The numbers tell the real story. Meta’s got an 18.4% annual revenue growth rate with EPS chugging along at nearly 30%. 

They’re dropping $64 to $72 billion this year alone, most of it into AI infrastructure that will power this advertising revolution. 

And here’s the beautiful part: Meta isn’t just participating in the attention economy anymore. They’re building the tollbooth, the road, and the map app.

Sure, Google (GOOGL) and Amazon (AMZN) are throwing money at AI like sailors on shore leave, but Meta has the holy trinity: the eyeballs, the engagement, and the tools to turn a grainy cupcake photo into an irresistible buying impulse. 

They don’t just know what you want. They know exactly how you want to be sold to.

So while Wall Street sleeps and traditional agencies polish their awards, the revolution is quietly happening in college dorm rooms with AI ad generators and plates of homemade cookies. Don Draper once said, “If you don’t like what’s being said, change the conversation.” 

Meta’s AI isn’t just changing the conversation. It’s firing the creative director, automating the pitch meeting, and locking down every prime-time slot while the old Mad Men are still arguing about font choices.

Who knew the death of Madison Avenue would taste so sweet?

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2025-06-13 16:58:512025-06-13 17:00:27THE DEATH OF MAD MEN
Page 40 of 49«‹3839404142›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top